Patents Assigned to Telesis Bio Inc.
  • Patent number: 11884916
    Abstract: The present invention provides materials and methods useful for error correction of nucleic acid molecules. In one embodiment of the invention, a first plurality of double-stranded nucleic acid molecules having a nucleotide mismatch are fragmented by exposure to a molecule having unidirectional mismatch endonuclease activity. The nucleic acid molecules are cut at the mismatch site or near the mismatch site, leaving a double-stranded nucleic acid molecule having a mismatch at the end or near end of the molecule. The nucleic acid molecule is then exposed to a molecule having unidirectional exonuclease activity to remove the mismatched nucleotide. The missing nucleotides can then be filled in by the action of, e.g., a molecule having DNA polymerase activity. The result is double-stranded nucleic acid molecules with a decreased frequency of nucleotide mismatches.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: January 30, 2024
    Assignee: Telesis Bio Inc.
    Inventors: Daniel G Gibson, Nicky Caiazza, Toby H. Richardson
  • Patent number: 11746321
    Abstract: The invention provides engineered Vibrio sp. organisms that comprise a genetic modification to either or both of the lpxL and/or lpxM genes. The organisms score substantially lower in an in vitro endotoxin assay versus the unmodified or wild type organism. The organisms preserve substantially the growth rate of the corresponding unmodified organisms. The organisms can also have an exogenous nucleic acid cloned in the organism, or an exogenous nucleic acid encoding a protein, polypeptide, or peptide expressed by the organism, and optionally secreted from the organism.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: September 5, 2023
    Assignee: Telesis Bio Inc.
    Inventors: Matthew T Weinstock, Daniel G. Gibson, Daniel Strimling
  • Patent number: 11618029
    Abstract: The present invention provides a system for receiving biological sequence information and activating the synthesis of a biological entity. The system has a receiving unit for receiving a signal encoding biological sequence information transmitted from a transmitting unit. The transmitting unit can be present at a remote location from the receiving unit. The system also has an assembly unit connected to the receiving unit, and the assembly unit assembles the biological entity according to the biological sequence information. Thus, according to the present invention biological sequence information can be digitally transmitted to a remote location and the information converted into a biological entity, for example a protein useful as a vaccine, immediately upon being received by the receiving unit and without further human intervention after preparing the system for receipt of the information.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: April 4, 2023
    Assignee: Telesis Bio Inc.
    Inventors: J. Craig Venter, Daniel Gibson, John E. Gill